Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Polygon Therapeutics Logo
Polygon Therapeutics Growth Score
57
CB Rank
320809
Heat Score
74
Polygon Therapeutics develops innovative biomedicines for the treatment of cardiovascular diseases.
Founded
obfuscation
PrivateNon-equity Assistance Paris, Ile-de-France, France1-10 www.polygon.care
Biotechnology
Health Care
Therapeutics
Wellness
Overview

Polygon Therapeutics
Growth Score
57
Heat Score
74

Growth Score57
-1 pts
in past quarter
Heat Score 74
3 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Polygon Therapeutics

CB Rank
320809
Polygon Therapeutics develops innovative biomedicines for the treatment of cardiovascular diseases.
Founded
obfuscation
PrivateNon-equity Assistance Paris, Ile-de-France, France1-10 www.polygon.care
Biotechnology
Health Care
Therapeutics
Wellness

Funding Rounds

Non-equity Assistance
OBF
in
obfuscation

Details

Legal Name POLYGON Therapeutics, SAS.
Operating Status Active
Company Type For Profit
About the Company
Polygon Therapeutics develops innovative biomedicines for the treatment of cardiovascular diseases.
Predictions & Insights

Growth Insight

See this Growth Insight
Polygon Therapeutics is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Growth Prediction

See this Growth Prediction

Products & Services

PLG-101
A monoclonal antibody targeting CD8+ T cells to reduce cardiac damage in acute myocardial infarction patients.
CARDINAL Platform
A cardio-immunology platform supporting drug development, biomarker discovery, and bio-imaging programs for cardiovascular diseases.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Non Equity Assistance - Polygon Therapeutics Logo
Non Equity Assistance - Polygon Therapeutics
1
obfuscation
AGORANOVNon-equity Assistance
obfuscation
Non Equity Assistance - Polygon Therapeutics Logo
Non Equity Assistance - Polygon Therapeutics
1
obfuscation
AGORANOVNon-equity Assistance
obfuscation
Non Equity Assistance - Polygon Therapeutics Logo
Non Equity Assistance - Polygon Therapeutics
1
obfuscation
AGORANOVNon-equity Assistance
obfuscation
Non Equity Assistance - Polygon Therapeutics Logo
Non Equity Assistance - Polygon Therapeutics
1
obfuscation
AGORANOVNon-equity Assistance
obfuscation
Non Equity Assistance - Polygon Therapeutics Logo
Non Equity Assistance - Polygon Therapeutics
1
obfuscation
AGORANOVNon-equity Assistance

Funding Rounds

Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Non Equity Assistance - Polygon Therapeutics Logo
Non Equity Assistance - Polygon Therapeutics
1
obfuscation
AGORANOVNon-equity Assistance
obfuscation
Non Equity Assistance - Polygon Therapeutics Logo
Non Equity Assistance - Polygon Therapeutics
1
obfuscation
AGORANOVNon-equity Assistance
obfuscation
Non Equity Assistance - Polygon Therapeutics Logo
Non Equity Assistance - Polygon Therapeutics
1
obfuscation
AGORANOVNon-equity Assistance
obfuscation
Non Equity Assistance - Polygon Therapeutics Logo
Non Equity Assistance - Polygon Therapeutics
1
obfuscation
AGORANOVNon-equity Assistance
obfuscation
Non Equity Assistance - Polygon Therapeutics Logo
Non Equity Assistance - Polygon Therapeutics
1
obfuscation
AGORANOVNon-equity Assistance

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
AGORANOV Logo
AGORANOV
Yes
Non Equity Assistance - Polygon Therapeutics Logo
Non Equity Assistance - Polygon Therapeutics
—
AGORANOV Logo
AGORANOV
Yes
Non Equity Assistance - Polygon Therapeutics Logo
Non Equity Assistance - Polygon Therapeutics
—
AGORANOV Logo
AGORANOV
Yes
Non Equity Assistance - Polygon Therapeutics Logo
Non Equity Assistance - Polygon Therapeutics
—
AGORANOV Logo
AGORANOV
Yes
Non Equity Assistance - Polygon Therapeutics Logo
Non Equity Assistance - Polygon Therapeutics
—
AGORANOV Logo
AGORANOV
Yes
Non Equity Assistance - Polygon Therapeutics Logo
Non Equity Assistance - Polygon Therapeutics
—
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Contacts 2
News

News and Press

News•Jun 10, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Feb 2, 2024
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

1,105
-12.09%
 in past month

IT Spend

$67.7KThis year, Polygon Therapeutics is projected to spend $67.7K on IT, according to Aberdeen.

Active Website Tech Count

4Polygon Therapeutics is actively using 4 technologies for its website, according to BuiltWith. These include Common Crawl, Euro, and  CommonCrawl Top 10m.

Total IP

2The intellectual property of Polygon Therapeutics includes 2 registered patents primarily in the 'Organic Chemistry' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Polygon Therapeutics's headquarters? Polygon Therapeutics is located in Paris, Ile-de-France, France.Who invested in Polygon Therapeutics? Polygon Therapeutics is funded by AGORANOV.When was the last funding round for Polygon Therapeutics? Polygon Therapeutics closed its last funding round on
obfuscation
from a Non-equity Assistance round.Who are Polygon Therapeutics's competitors? Alternatives and possible competitors to Polygon Therapeutics may include Climb Bio, Tenaya Therapeutics, and  Cytokinetics.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(1f7f9f7 1)
|